Does Retatrutide Affect Birth Control? The Oral-Contraceptive Study
See what the completed retatrutide oral-contraceptive study tested, whether results are posted and how absorption measurements differ from pregnancy prevention.
FormBlends Editorial Research · Updated 2026-10-03
Retatrutide is investigational and is not FDA-approved. FDA states that it cannot be used in compounding under federal law. FormBlends does not prescribe, compound or sell retatrutide.
A dedicated retatrutide study tested blood levels of the oral-contraceptive ingredients ethinyl estradiol and drospirenone. Its ClinicalTrials.gov record shows completion, but no results were posted when checked on October 3, 2026. The record therefore identifies a relevant study without establishing whether retatrutide changes contraceptive effectiveness.
The study that directly addresses pill absorption
NCT06039826 is a phase 1 study with actual enrollment of 46 postmenopausal women aged 40 to 60 with BMI 27 to 40. It combined retatrutide with ethinyl estradiol and drospirenone. The study completed on July 11, 2024; the registry's last posted update is July 26, 2024.
The six primary outcomes are three concentration measurements for each of the two pill ingredients: exposure over 24 hours, peak concentration and time to that peak. The result section was absent in the registry response reviewed for this article. Completion is a study-status field, not a published interaction result.
What the three measurements would tell us
| Measurement | Question it answers | What it does not answer by itself |
|---|---|---|
| AUC over 24 hours | How much exposure occurred over the measured interval? | A pregnancy-prevention rate |
| Maximum concentration, Cmax | How high was the observed peak? | Whether overall exposure changed by the same amount |
| Time to maximum concentration, Tmax | When did the peak occur? | Whether a later peak means contraceptive failure |
Imagine two illustrative concentration curves: one peaks later but has the same overall area; another has both a lower peak and a lower area. Those are different findings. This is an explanation of how to read the measurements, not an observed result from the retatrutide study.
Why the participant population matters
A pharmacokinetic study can examine drug exposure without measuring pregnancy prevention. Here the enrolled population was postmenopausal. The registered primary outcomes do not count ovulations, pregnancies or contraceptive failures. A future concentration report would answer the exposure question it measured, rather than automatically supplying a failure rate in women using contraception.
Does this cover every birth-control method?
The specified intervention contains two oral ingredients. It does not directly test every contraceptive pill formulation, an implant, an intrauterine device, a patch or a vaginal ring. Evidence should identify the exact formulation and route before making an all-methods claim.
The useful distinction is the evidence question: pill absorption, contraceptive effectiveness and fertility are separate endpoints. See the phase 2 obesity record and its publication for weight outcomes; those results do not fill in the missing oral-contraceptive concentration results.
A checklist for a future interaction report
- Confirm that the tested drug is retatrutide and identify the exact contraceptive ingredients.
- Look for actual results, rather than a registry marked completed.
- Separate exposure, peak concentration and timing changes.
- Check the participant population and the comparison used.
- Identify whether the report measures pregnancy prevention or only blood concentrations.
Frequently asked questions
Has a retatrutide and oral-contraceptive study been conducted?
Yes. NCT06039826 records a completed phase 1 study with 46 participants. No results were posted in that registry record at this review.
Can we say retatrutide makes the pill fail?
The checked record does not establish that conclusion. It specifies concentration endpoints and provides no posted numerical results or contraceptive-failure rate.
Can we say there is no interaction?
The same missing result also prevents that conclusion. A registered study is evidence that a question was investigated, not evidence of its answer.
Absence of a reported interaction is not proof that no interaction exists. These research limitations do not support instructions about spacing medicines, changing another prescription, stacking peptides or selecting a combination dose.